AMHR2 and cancer: Most transgenics have focused on the use of the anti-Mullerian hormone type II receptor (Amhr2 or MISIIR) promoter to drive tumor suppressor knockout or oncogene activation, but its expression in granulosa cells as well as both ovarian epithelium and fimbria can confound the results and make the origins of such cancers unclear (5).